Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05882266

The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals With Cardiovascular(CVD) Risk

The goal of this clinical trial is to investigate the outcome of plant-based omega-3 intervention on lipid profile and blood pressure after 12 weeks and to study the molecular markers associated with the incidence of CVD risk. The main questions it aims to answer are:

* What is the role of plant-based omega-3 intervention on lipid profile and blood pressure of individuals with CVD risk after 12 weeks? * What is the association between unique molecular markers and plant-based omega-3 intervention among individuals with CVD risk?

Participants will be subjected to two groups:

* Treatment group: Receive standard dietary therapy and plant-based omega-3 supplemental beverage consumed once daily during breakfast * Control group: Receive only standard dietary therapy

Researcher will compare between treatment and control group to see the effect of plant based omega-3 on lipid profile and blood pressure after 12 weeks

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beacon Hospital Sdn Bhd

Petaling Jaya, Selangor, 46050, Malaysia

Location contact

Geeta Appanah, PhD

SUB_INVESTIGATOR

Mohd Hamzah Kamaruzaman, FRCS, Md

SUB_INVESTIGATOR

Sook Hui Tay

CONTACT

[email protected]

+60163040540

Syamimi Samah, PhD

SUB_INVESTIGATOR

About this study

This study is a single-blinded, randomised controlled, parallel clinical trial with the aim to compare the effect of plant-based omega-3 versus standard dietary therapy among individuals with CVD risk for 12 weeks. The randomisation will be done by an independent researcher.

Following, the sample size for this study is 72 individuals with CVD risk, calculated based from two previous studies that investigated the effect of plant based omega 3 intake on cardiometabolic risk individuals and dairy beverages intake among type 2 diabetes mellitus patient.

Besides that, demographic information, medical history, medication history, social history, family history and nutritional information will be gathered using the Case Report Form (CRF) along with 3 days diet record and International Physical Activity Questionnaire (IPAQ) for physical activities assessment. Furthermore, anthropometric data, pain assessment, product sensory evaluation and compliance assessment will also be assessed using the same CRF form.

Correspondingly, 10-hour fasting blood sample (20ml) will be collected from a total of 72 subjects (treatment group, n=36 and control group, n= 36, respectively) for the blood test profiles and genotyping microarray analysis. Subjects need to avoid any alcohol intake, unusual amounts of physical activity and unusual amounts of food intake within 24-hour of blood taking. All the biochemical analyses will be done and entirely sponsored by Beacon Precision Diagnostics Sdn. Bhd. The study will be conducted in compliance with ethical principles outlined in the Declaration of Helsinki and Malaysian Good Clinical Practice Guideline.

Also, subjects shall be informed of the study during their usual clinic visits. They will be requested to contact investigators if they are interested. An appointment will be made where the subject information sheet will be provided and explained to them. If they are willing to participate, the consent forms will be signed and dated. If they need to, they are allowed to take the information sheet home to consult with their family members and another day for getting consent arranged. This study is an independent study, subjects can choose to withdraw at any time. Lastly, the investigators declare they have no conflict of interest.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Malaysian aged 18 to 60 years
  • BMI between 18.5 and 39.9 kg/m2
  • Not on any weight loss therapy
  • Is able to commit to 12 weeks of either intervention
  • Presented signs of metabolic syndrome or moderate hypercholesterolemia

Exclusion criteria

  • Those who are pregnant or lactating
  • Had undergone bariatric surgery
  • Who have acute illnesses such as flu
  • Who has any diabetes-related chronic complications except hypertension and hyperlipidemia
  • Having chronic diseases in particular cancer, liver, kidney, heart disease, stroke, or psychiatric illness
  • Having eating disorder or hypothyroidism

Treatment and study plan

Plant Omega

Dietary Supplement

A commercial plant-based omega-3 beverage consumed once daily during breakfast

Dietary therapy only

Other

Standard dietary therapy

Primary outcomes

  1. Changes in lipid profile after 12 weeks intervention of plant based omega 3

    Time frame: Baseline and Week 12

    Changes in the lipid profile level of LDL, HDL, total cholesterol, triglyceride using standard metric (mmol/L)

  2. Changes in the blood pressure after 12 weeks intervention of plant based omega 3

    Time frame: Baseline and Week 12

    Changes in both systolic and diastolic blood pressure using the standard unit (mmHg)

  3. Changes in microarray gene expression profile in blood from individual with CVD risk

    Time frame: Baseline and Week 12

    Changes in microarray gene expression profile in blood from individual with CVD risk, in response to the 12 weeks intake of plant based omega 3

Secondary outcomes

  1. Changes in anti-inflammatory effect of plant-based omega-3 after 12 weeks

    Time frame: Baseline, Week 12

    Changes in high-sensitivity C-Reactive Protein (hs-CRP) using standard metric (mg/L)

  2. Changes in fasting blood glucose after 12 weeks intervention of plant based omega-3

    Time frame: Baseline, Week 12

    Changes in fasting blood glucose using standard metric (mmol/L)

  3. Changes in glycated hemoglobin after 12 weeks intervention of plant based omega-3

    Time frame: Baseline, Week 12

    Changes in glycated hemoglobin (hbA1c) using standard metric (%)

  4. Changes in quality of life of individuals with CVD risk, before and after the consumption of plant-based omega 3 for 12 weeks

    Time frame: Baseline, Week 12

    Changes in pain score assess using the short 0-10 numeric pain scale. It is a validated self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain).

Study contacts

Contact information is provided by the study sponsor or research team.

Soon Peng Gew

CONTACT

[email protected]

+60162101615

Sponsors and collaborators

Lead sponsor

Universiti Putra Malaysia

Other

Collaborators

  • Beacon Hospital Sdn Bhd

Registry information

Official study title

The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals With Cardiovascular(CVD) Risk at Beacon Hospital in Selangor

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 31, 2023
Registry last updated
Dec 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.